Catalog Number:
CPTC-BRCA1-1
RRID:
AB_2617225
Target Antigen:
Breast Cancer 1, Early Onset Peptide 1
Isotype:
IgG1
Species:
Mouse Monoclonal Antibody
Last Updated:
03/25/2022
Antigen Recognition(s):
Peptide, Phosphorylation
Thematic Panel(s):
DNA Damage Response (DDR) Pathway
Result: Positive
Immuno-Precipitation Mass Spectrometry using CPTC-BRCA1-1 antibody with CPTC-BRCA1 peptide 1 (phosphorylated) as the target antigen.
Result: Positive
Immuno-Precipitation Mass Spectrometry using CPTC-BRCA1-1 antibody with CPTC-BRCA1 peptide 1 (non-phosphorylated) as the target antigen.
Result: Negative
Western blot using CPTC-BRCA1-1 as primary antibody against HT-29 (lane 2), HeLa (lane 3), MCF7 (lane 4), HL-60 (lane 5), Hep G2 (lane 6), and MCF7 (lane 7) whole cell lysates. Expected molecular weight - 208 kDa, 7 kDa, 85 kDa, 206 kDa, 81 kDa, 78 kDa, 210 kDa, and 202 kDa. Molecular weight standards are also included (lane 1).
Result: Negative
Automated western blot using CPTC-BRCA1-1 as primary antibody against against HT-29 (lane 2), HeLa (lane 3), MCF7 (lane 4), HL-60 (lane 5), Hep G2 (lane 6), and MCF7 (lane 7) whole cell lysates. Expected molecular weight - 208 kDa, 7 kDa, 85 kDa, 206 kDa, 81 kDa, 78 kDa, 210 kDa, and 202 kDa. Molecular weight standards are also included (lane 1).
Catalog Number:
CPTC-BRCA1-2
RRID:
AB_2722030
Target Antigen:
Breast Cancer 1, Early Onset Peptide 1
Isotype:
IgG1
Species:
Mouse Monoclonal Antibody
Last Updated:
03/25/2022
Antigen Recognition(s):
Peptide
Thematic Panel(s):
DNA Damage Response (DDR) Pathway
Result: Positive
Immuno-Precipitation Mass Spectrometry using CPTC-BRCA1-2 antibody with CPTC-BRCA1 peptide 1 (non-phosphorylated) as the target antigen.
Result: Negative
CPTC-BRCA1-2 antibody did not react with phosphorylated BRCA1 peptide 1 using the IPMS procedure
Result: Negative
Western blot using CPTC-BRCA1-2 as primary antibody against HT-29 (lane 2), HeLa (lane 3), MCF7 (lane 4), HL-60 (lane 5), Hep G2 (lane 6), and MCF7 (lane 7) whole cell lysates. Expected molecular weight - 208 kDa, 7 kDa, 85 kDa, 206 kDa, 81 kDa, 78 kDa, 210 kDa, and 202 kDa. Molecular weight standards are also included (lane 1).
Result: Negative
Automated western blot using CPTC-BRCA1-2 as primary antibody against HT-29 (lane 2), HeLa (lane 3), MCF7 (lane 4), HL-60 (lane 5), Hep G2 (lane 6), and MCF7 (lane 7) whole cell lysates. Expected molecular weight - 208 kDa, 7 kDa, 85 kDa, 206 kDa, 81 kDa, 78 kDa, 210 kDa, and 202 kDa. Molecular weight standards are also included (lane 1).
Catalog Number:
CPTC-BRCA1-3
Target Antigen:
Breast Cancer 1, Early Onset Peptide 1
Isotype:
IgG1
Species:
Mouse Monoclonal Antibody
Last Updated:
03/25/2022
Antigen Recognition(s):
Peptide, Phosphorylation
Thematic Panel(s):
DNA Damage Response (DDR) Pathway
Result: Positive
Immuno-Precipitation Mass Spectrometry using CPTC-BRCA1-3 antibody with CPTC-BRCA1 peptide 1 (non-phosphorylated) as the target antigen.
Result: Negative
CPTC-BRCA1-3 antibody did not react with phosphorylated BRCA1 peptide 1 using the IPMS procedure
Result: Negative
Western blot using CPTC-BRCA1-3 as primary antibody against HT-29 (lane 2), HeLa (lane 3), MCF7 (lane 4), HL-60 (lane 5), Hep G2 (lane 6), and MCF7 (lane 7) whole cell lysates. Expected molecular weight - 208 kDa, 7 kDa, 85 kDa, 206 kDa, 81 kDa, 78 kDa, 210 kDa, and 202 kDa. Molecular weight standards are also included (lane 1).
Result: Negative
Automated western blot using CPTC-BRCA1-3 as primary antibody against HT-29 (lane 2), HeLa (lane 3), MCF7 (lane 4), HL-60 (lane 5), Hep G2 (lane 6), and MCF7 (lane 7) whole cell lysates. Expected molecular weight - 208 kDa, 7 kDa, 85 kDa, 206 kDa, 81 kDa, 78 kDa, 210 kDa, and 202 kDa. Molecular weight standards are also included (lane 1).
Catalog Number:
CPTC-BRCA1-4
Target Antigen:
Breast Cancer 1, Early Onset Peptide 1
Isotype:
IgG
Species:
Rabbit Monoclonal Antibody
Last Updated:
02/02/2024
Antigen Recognition(s):
Peptide, Phosphorylation
Thematic Panel(s):
DNA Damage Response (DDR) Pathway
Result: Positive
Immuno-MRM chromatogram of CPTC-BRCA1-4 antibody (see CPTAC assay portal for details: https://assays.cancer.gov/CPTAC-3219)
Data provided by the Paulovich Lab, Fred Hutch (https://research.fredhutch.org/paulovich/en.html)
Result: Negative
Western blot using CPTC-BRCA1-4 as primary antibody against HT-29 (lane 2), HeLa (lane 3), MCF7 (lane 4), HL-60 (lane 5), Hep G2 (lane 6), and MCF7 (lane 7) whole cell lysates. Expected molecular weight - 208 kDa, 7 kDa, 85 kDa, 206 kDa, 81 kDa, 78 kDa, 210 kDa, and 202 kDa. Molecular weight standards are also included (lane 1).
Result: Negative
Automated western blot using CPTC-BRCA1-4 as primary antibody against HT-29 (lane 2), HeLa (lane 3), MCF7 (lane 4), HL-60 (lane 5), Hep G2 (lane 6), and MCF7 (lane 7) whole cell lysates. Expected molecular weight - 208 kDa, 7 kDa, 85 kDa, 206 kDa, 81 kDa, 78 kDa, 210 kDa, and 202 kDa. Molecular weight standards are also included (lane 1).
NCI Identification Number:
00088
Antigen Name:
Breast Cancer 1, Early Onset Peptide 1
CPTC Name:
CPTC-BRCA1 Peptide 1
Aliases:
Breast Cancer 1, Early Onset; RNF53; RING Finger Protein 53; BROVCA1; PNCA4; PSCP; BRCA1/BRCA2-Containing Complex; Protein Phosphatase 1; Regulatory Subunit 53; Subunit 1; BRCAI; BRCC1; IRIS; PPP1R53; BRCA1/BRCA2-Containing Complex, Subunit 1; Breast And Ovarian Cancer Susceptibility Protein1; Breast Cancer Type 1 Susceptibility Protein; Protein Phosphatase 1, Regulatory Subunit 53; EC 6.3.2.
Function:
This gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified.
BRCA1 (breast cancer 1, early onset) is a protein-coding gene. Diseases associated with BRCA1 include primary peritoneal carcinoma, and hereditary site-specific ovarian cancer syndrome. GO annotations related to this gene include RNA binding and enzyme binding.
E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. It is unclear whether it also mediates the formation of other types of polyubiquitin chains. The E3 ubiquitin-protein ligase activity is required for its tumor suppressor function. The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Regulates centrosomal microtubule nucleation. Required for normal cell cycle progression from G2 to
mitosis. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks. Component of the BRCA1-RBBP8 complex which regulates CHEK1 activation and controls cell cycle G2/M checkpoints on DNA damage via BRCA1-mediated ubiquitination of RBBP8.
Chromosomal Localization:
17q21.32
Accession Number:
NP_009225.1
UniProt Accession Number:
P38398
DNA Source:
N/A
Immunogen:
Synthetic Peptide
Vector Name:
N/A
Extinction Coefficient:
Buffers:
Expressed Sequence:
NYP(pS)QEELIK
Native Sequence:
Calculated Isoelectric Point:
0
Molecular Weight:
1100
Last Updated:
09/01/2020
No SOPs available.
Get it for free at Adobe.com